Chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common chronic immune-mediated neuropathy. It affects peripheral nerves and roots. CIDP has no biomarkers. It may be monophasic or ...
Two phase 3 studies are currently underway testing riliprubart in people with CIDP as a potential first-in-class treatment Japanese Ministry of Health, Labour and Welfare decision adds to similar ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved Takeda Pharmaceutical’s Hyqvia, coformulated with Halozyme's Enhanze drug delivery ...
CIDP is a treatable condition that affects the peripheral nervous system. IVIG, plasma exchange, and corticosteroid therapy are the first-line treatment options, but a newer medication for adults has ...
"Chronic Inflammatory Demyelinating Polyneuropathy Clinical Trials"DelveInsight's,“Chronic inflammatory demyelinating polyneuropathy (CIDP)- Pipeline Insight, 2025” report provides comprehensive ...
KING OF PRUSSIA, Pa., Dec. 9, 2019 /PRNewswire/ -- Global biotherapeutics leader CSL Behring announced today that Hizentra received orphan-drug exclusivity from the U.S. Food and Drug Administration ...
Dublin, Aug. 11, 2025 (GLOBE NEWSWIRE) -- The "Chronic Inflammatory Demyelinating Polyneuropathy Market - A Global and Regional Analysis: Focus on Distribution Channel, Route of Administration, and ...
Chronic inflammatory demyelinating polyneuropathy is an immune-mediated neuropathy that affects the peripheral motor and sensory nerves. The symptoms are of a slowly progressive numbness and tingling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback